Nuclear and radiochemistry

Radiopharmaceuticals and Nuclear Medicine

How targeting molecules carry diagnostic and therapeutic radionuclides into disease sites, balancing decay kinetics, organ clearance, and cellular radiation damage.

IntuitionIntuition: molecular beacons inside the living body

Imagine sending microscopic scouts through the bloodstream that bind exclusively to tumor cells while carrying tiny radioactive lanterns. Because human tissue is largely transparent to high-energy gamma rays, external detectors can pinpoint exactly where these scouts accumulate without surgical incisions. If the lantern is swapped for a particle-emitting source, the radiation damages cancer cell DNA at microscopic ranges while sparing surrounding healthy tissue.

SchoolSchool level: diagnostic imaging modalities and tracer chemistry

Common clinical tracers exemplify diverse radiolabelling strategies. Technetium-99m ($t_{1/2} = 6.01\text{ h}$, $140.5\text{ keV}$ $\gamma$) is eluted from a $\ce{^{99}Mo/^{99m}Tc}$ alumina generator as pertechnetate $[\ce{^{99m}TcO4}]^-$; reduction by $\ce{Sn^2+}$ enables chelation into $\ce{^{99m}Tc-sestamibi}$ (myocardial perfusion), $\ce{^{99m}Tc-MDP}$ (bone metastases), or $\ce{^{99m}Tc-MAA}$ (pulmonary embolism). For PET, cyclotron-produced fluorine-18 ($t_{1/2} = 109.8\text{ min}$) is synthesized into $[\ce{^{18}F}]\text{FDG}$ (2-deoxy-2-$[\ce{^{18}F}]$fluoro-D-glucose). Cancer cells overexpress GLUT transporters and take up $[\ce{^{18}F}]\text{FDG}$ rapidly (Warburg effect); intracellular hexokinase phosphorylates it to $[\ce{^{18}F}]\text{FDG-6-phosphate}$, which cannot undergo glycolysis or isomerize, trapping radioactivity inside malignant tissue.

UndergraduateUndergraduate: biokinetics, chelators, and effective half-life

Radiometals ($\ce{Lu^3+}, \ce{Ac^3+}, \ce{Y^3+}, \ce{Ga^3+}$) cannot be administered as uncomplexed aqueous ions because rapid in vivo hydrolysis and serum protein transchelation cause catastrophic bone marrow or liver toxicity. They are anchored using bifunctional chelating agents (BFCAs) that couple a metal-binding macrocycle to a targeting biomolecule via a peptide spacer. The macrocycle DOTA ($1,4,7,10$-tetraazacyclododecane-$1,4,7,10$-tetraacetic acid) forms exceptionally stable octadentate complexes ($\log K > 22$) with trivalent lanthanides ($\ce{Lu^3+}$) and actinides ($\ce{Ac^3+}$), preventing transchelation by serum transferrin. For smaller octahedral ions like $\ce{Ga^3+}$, NOTA ($1,4,7$-triazacyclononane-$1,4,7$-triacetic acid) allows rapid quantitative radiolabelling at ambient temperature.

AdvancedAdvanced: theranostics, linear energy transfer, and MIRD dosimetry

The theranostics paradigm couples diagnostic imaging and targeted therapy using the same molecular vector. A patient with neuroendocrine tumors is first imaged using $[\ce{^{68}Ga}]\text{Ga-DOTATATE}$ PET to verify somatostatin receptor subtype 2 (SSTR2) density; if positive, therapy is delivered using $[\ce{^{177}Lu}]\text{Lu-DOTATATE}$ (Lutathera). The clinical outcome depends heavily on the Linear Energy Transfer (LET) of the therapeutic emission: beta particles ($\ce{^{177}Lu}, \ce{^{131}I}$) have low LET ($\sim 0.2\text{ keV}/\mu\text{m}$) and long ranges ($1\text{-}5\text{ mm}$), causing isolated single-strand breaks and a crossfire effect that sterilizes adjacent tumor cells. In contrast, alpha particles ($\ce{^{223}Ra}, \ce{^{225}Ac}$) have high LET ($80\text{-}100\text{ keV}/\mu\text{m}$) and ultrashort paths ($40\text{-}80\ \mu\text{m}$), depositing dense ionization clusters that inflict non-repairable double-strand DNA breaks independent of tissue oxygenation.

In internal dosimetry, the Medical Internal Radiation Dose (MIRD) schema calculates the absorbed dose $D(r_T)$ delivered to a target tissue $r_T$ by summing contributions from all source organs $r_S$. Here $\tilde{A}(r_S)$ represents the cumulated activity (total number of radioactive disintegrations occurring in the source organ over all time), and $S(r_T \leftarrow r_S)$ is the radionuclide-specific and anatomy-dependent $S$-value (absorbed dose per unit cumulated activity, in $\text{Gy}/(\text{Bq}\cdot\text{s})$), which accounts for radiation yield, particle energies, and cross-organ absorbed energy fractions. Securing medical isotope precursors like $\ce{^{99}Mo}$ ($t_{1/2} = 65.9\text{ h}$) is an active engineering frontier, transitioning globally from reactor fission of high-enriched uranium (HEU) to non-proliferative low-enriched uranium (LEU) and direct accelerator production via $\ce{^{100}Mo}(p,2n)\ce{^{99m}Tc}$.